2025 ASCO-话题@MedSci

#2025 ASCO#

0篇内容 | 56人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2268505, encodeId=f1dc2268505a5, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a>, objectTitle=乳腺癌无进展生存期延长近7个月！“疾病未进展先换药”策略或改写临床实践 | 2025 ASCO速递, objectType=article, longId=881094, objectId=7113881094bb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240513/1715588347041_5579292.jpg, objectUrl=/article/show_article.do?id=7113881094bb, replyNumber=0, likeNumber=3, createdTime=9小时前, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7113881094bb, moduleTitle=乳腺癌无进展生存期延长近7个月！“疾病未进展先换药”策略或改写临床实践 | 2025 ASCO速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7113881094bb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268193, encodeId=c952226819313, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a>, objectTitle=张涛教授团队:晚期结直肠癌新突破，创新疗法点燃“冷肿瘤”免疫治疗新希望 | 2025 ASCO, objectType=article, longId=880715, objectId=3599880e1591, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240525/1716651988616_92910.png, objectUrl=/article/show_article.do?id=3599880e1591, replyNumber=0, likeNumber=9, createdTime=2025-06-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3599880e1591, moduleTitle=张涛教授团队:晚期结直肠癌新突破，创新疗法点燃“冷肿瘤”免疫治疗新希望 | 2025 ASCO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3599880e1591)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268194, encodeId=3452226819437, content=<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a> <a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a>, objectTitle=死亡风险显著降低40%！双特异性抗体为肺癌治疗提供新选择 | 2025 ASCO速递, objectType=article, longId=880720, objectId=27e4880e2059, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241106/1730887855049_8538692.jpg, objectUrl=/article/show_article.do?id=27e4880e2059, replyNumber=0, likeNumber=0, createdTime=2025-06-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=27e4880e2059, moduleTitle=死亡风险显著降低40%！双特异性抗体为肺癌治疗提供新选择 | 2025 ASCO速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27e4880e2059)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268068, encodeId=09bc2268068e9, content=<a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a> <a href='/topic/show?id=1e8312e581ce' target=_blank style='color:#2F92EE;'>#复发/难治性皮肤T细胞淋巴瘤#</a>, objectTitle=李志铭教授：抗CCR8抗体治疗R/R CTCL I期研究突破，显著延长PFS且安全性可控|2025 ASCO, objectType=article, longId=880489, objectId=3a9588048900, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240605/1717579406246_5579292.png, objectUrl=/article/show_article.do?id=3a9588048900, replyNumber=0, likeNumber=9, createdTime=2025-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3a9588048900, moduleTitle=李志铭教授：抗CCR8抗体治疗R/R CTCL I期研究突破，显著延长PFS且安全性可控|2025 ASCO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a9588048900)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268069, encodeId=3bd722680693a, content=<a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤单抗#</a> <a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a>, objectTitle=肿瘤近乎消失患者比例翻2.6倍！免疫联合标准治疗为胃癌患者带来显著生存获益 | 2025 ASCO速递, objectType=article, longId=880491, objectId=4a5588049138, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220804/1659603269411_8252897.webp, objectUrl=/article/show_article.do?id=4a5588049138, replyNumber=0, likeNumber=8, createdTime=2025-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4a5588049138, moduleTitle=肿瘤近乎消失患者比例翻2.6倍！免疫联合标准治疗为胃癌患者带来显著生存获益 | 2025 ASCO速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a5588049138)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268071, encodeId=67ec22680e142, content=<a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a> <a href='/topic/show?id=6fd512e58371' target=_blank style='color:#2F92EE;'>#复发或难治性骨肉瘤#</a>, objectTitle=叶峰教授团队：靶向CSF-1R/DDR1/VEGFR2的骨肉瘤新疗法Ib期数据亮眼 | 2025 ASCO, objectType=article, longId=880592, objectId=d70e880592c0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720150555131_5579292.jpg, objectUrl=/article/show_article.do?id=d70e880592c0, replyNumber=0, likeNumber=16, createdTime=2025-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d70e880592c0, moduleTitle=叶峰教授团队：靶向CSF-1R/DDR1/VEGFR2的骨肉瘤新疗法Ib期数据亮眼 | 2025 ASCO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d70e880592c0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268079, encodeId=54a222680e948, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=e9e289e771c' target=_blank style='color:#2F92EE;'>#血管舒缩症状#</a> <a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a>, objectTitle=用药一周即见效！新药可改善乳腺癌患者潮热、多汗等症状 | 2025 ASCO速递, objectType=article, longId=880722, objectId=df32880e22f5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240517/1715930918928_5579292.jpg, objectUrl=/article/show_article.do?id=df32880e22f5, replyNumber=0, likeNumber=8, createdTime=2025-06-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=df32880e22f5, moduleTitle=用药一周即见效！新药可改善乳腺癌患者潮热、多汗等症状 | 2025 ASCO速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df32880e22f5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2267911, encodeId=0b8f226e9115d, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=1a5a58e00ad' target=_blank style='color:#2F92EE;'>#新辅助治疗#</a> <a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a>, objectTitle=超95%肺癌患者存活超过5年！新辅助免疫治疗联合化疗带来长期生存获益 | 2025 ASCO速递, objectType=article, longId=880274, objectId=b4fc8802e483, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240508/1715158312120_92910.png, objectUrl=/article/show_article.do?id=b4fc8802e483, replyNumber=0, likeNumber=11, createdTime=2025-06-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b4fc8802e483, moduleTitle=超95%肺癌患者存活超过5年！新辅助免疫治疗联合化疗带来长期生存获益 | 2025 ASCO速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4fc8802e483)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2267912, encodeId=821d226e912f0, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a> <a href='/topic/show?id=20f812e54145' target=_blank style='color:#2F92EE;'>#2025 ASCO#</a>, objectTitle=生存结局双重获益，总生存期近16个月！这类卵巢癌或有新标准治疗方案 | 2025 ASCO速递, objectType=article, longId=880371, objectId=d61c8803e123, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240530/1717039503039_5579292.jpg, objectUrl=/article/show_article.do?id=d61c8803e123, replyNumber=0, likeNumber=10, createdTime=2025-06-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d61c8803e123, moduleTitle=生存结局双重获益，总生存期近16个月！这类卵巢癌或有新标准治疗方案 | 2025 ASCO速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d61c8803e123)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

肺癌新辅助治疗 2025 ASCO

2025-06-04发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #2025 ASCO#

乳腺癌无进展生存期延长近7个月！“疾病未进展先换药”策略或改写临床实践 | 2025 ASCO速递

9小时前发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#结直肠癌# #2025 ASCO#

张涛教授团队:晚期结直肠癌新突破，创新疗法点燃“冷肿瘤”免疫治疗新希望 | 2025 ASCO

2025-06-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#小细胞肺癌# #2025 ASCO#

死亡风险显著降低40%！双特异性抗体为肺癌治疗提供新选择 | 2025 ASCO速递

2025-06-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#2025 ASCO# #复发/难治性皮肤T细胞淋巴瘤#

李志铭教授：抗CCR8抗体治疗R/R CTCL I期研究突破，显著延长PFS且安全性可控|2025 ASCO

2025-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#度伐利尤单抗# #2025 ASCO#

肿瘤近乎消失患者比例翻2.6倍！免疫联合标准治疗为胃癌患者带来显著生存获益 | 2025 ASCO速递

2025-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#2025 ASCO# #复发或难治性骨肉瘤#

叶峰教授团队：靶向CSF-1R/DDR1/VEGFR2的骨肉瘤新疗法Ib期数据亮眼 | 2025 ASCO

2025-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #血管舒缩症状# #2025 ASCO#

用药一周即见效！新药可改善乳腺癌患者潮热、多汗等症状 | 2025 ASCO速递

2025-06-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #新辅助治疗# #2025 ASCO#

超95%肺癌患者存活超过5年！新辅助免疫治疗联合化疗带来长期生存获益 | 2025 ASCO速递

2025-06-04发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#卵巢癌# #2025 ASCO#

生存结局双重获益，总生存期近16个月！这类卵巢癌或有新标准治疗方案 | 2025 ASCO速递

2025-06-04发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务